Hovione has entered a co-promotion and collaboration agreement with Ligand to provide its customers with access to Ligand’s Captisol technology. Captisol, a chemically modified cyclodextrin, improves the solubility and stability of drugs and is currently used in six marketed products. The agreement allows Hovione to use Captisol technology in its solubilization programs, which include amorphous solid dispersions, crystal design and size reduction and control of particle size.   “Hovione is...